高级检索
当前位置: 首页 > 详情页

Real-World Utilization of Biologic and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis: Insights from Sweden and Germany

文献详情

资源类型:
Pubmed体系:
机构: [1]UCB, Allée de la Recherche 60, Anderlecht, 1070 Brussels, Belgium [2]Quantify Research, Hantverkargatan 8, 112 21 Stockholm, Sweden [3]Cytel, Inc, Potsdamer Str. 58, 10785 Berlin, Germany [4]Institute for Pharmacoeconomics and Drug Logistics, Alter Holzhafen 19, 23966 Wismar, Germany [5]Department of Clinical Neuroscience, Karolinska Institutet, Nobels VÃg 9, 17177 Stockholm, Sweden
出处:
ISSN:

关键词: Axial spondyloarthritis b/tsDMARDs Psoriatic arthritis Treatment regimens

摘要:
Real-world data on patient characteristics and dosing patterns for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are limited. This study assessed characteristics and dosing patterns in patients initiating a biologic or targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD).This cohort study included adult patients with PsA and axSpA newly initiating b/tsDMARDs, identified in the Swedish National Registers (2017-2021) and a German insurance claims database (2018-2021) from two regions (Saxony and Thuringia). Patient characteristics and dosing patterns were analyzed descriptively.Overall, 9414 (Sweden) and 2045 (Germany) patients with PsA and 7763 (Sweden) and 1756 (Germany) patients with axSpA were included. Patients with PsA were generally older and more often female than the patients with axSpA. Swedish patients were generally younger with fewer co-diagnoses than German patients. The most common co-diagnoses were psoriasis, hypertension, and joint pain. Most patients were b/tsDMARD-naïve and had prior nonsteroidal anti-inflammatory drug or corticosteroid use. Anti-tumor necrosis factor agents were most commonly used (Sweden: PsA 71.22%, axSpA 86.42%; Germany: PsA 41.66%, axSpA 79.67%). Secukinumab was the most frequently prescribed treatment with recommended dose escalation, followed by ixekizumab and guselkumab. For secukinumab, German patients typically received higher maintenance doses (300 mg vs 150 mg/month) than those in Sweden, especially in those without psoriasis. For ixekizumab, while all patients in Sweden received an 80 mg/month maintenance dose, some patients in Germany received a 160 mg/month maintenance dose. For guselkumab, some patients in Germany received higher-than-recommended maintenance doses; this pattern was not observed in Sweden.Differences between patient characteristics and dosing patterns were observed between patients with PsA and axSpA in Sweden and Germany. Treatment variations may reflect high prevalences of co-diagnoses, like psoriasis, or unmet therapeutic needs. This work serves as a first step towards future research for personalized treatment approaches to optimize treatment outcomes.© 2025. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 2 区 药学 3 区 医学:研究与实验
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 药学 3 区 医学:研究与实验
第一作者:
第一作者机构: [1]UCB, Allée de la Recherche 60, Anderlecht, 1070 Brussels, Belgium
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. [2]Detection of psoriatic arthritis in the finger joints by Thermoacoustic Tomography [3]Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis [4]SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights [5]Would previous use of TNF inhibitors affect the therapeutic effect of IL-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis: results from a systematic review. [6]Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis [7]The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis [8]NETWORK META-ANALYSIS OF EFFICACY OF PEMETREXED- OR BEVACIZUMAB-BASED REGIMENS IN FIRST-LINE AND MAINTENANCE TREATMENT FOR ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER [9]Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma [10]GEMOX与GDP方案治疗复发难治性非霍奇金淋巴瘤的疗效比较

资源点击量:59516 今日访问量:0 总访问量:4869 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号